On Feb 12, 2026, BIO reported earnings of 2.50 USD per share (EPS) for Q4 25, missing the estimate of 2.72 USD, resulting in a -7.97% surprise. Revenue reached 693.20 million, compared to an expected 695.65 million, with a -0.35% difference. The market reacted with a -12.26% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of 2.00 USD, with revenue projected to reach 594.76 million USD, implying an decrease of -20.00% EPS, and decrease of -14.20% in Revenue from the last quarter.